Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from PODD

Earnings Preview: What to Expect From Insulet's Report

Insulet is scheduled to release its fiscal fourth-quarter earnings next month, and analysts project a double-digit profit decline.

Barchart

Is Insulet Stock Outperforming the Dow?

Insulet has outperformed the Dow recently, and analysts remain strongly optimistic about the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Insulet Stock Will Climb or Sink?

As Insulet outperformed relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Insulet's Quarterly Earnings Preview: What You Need to Know

Insulet will release its third-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Barchart

Is Insulet Stock Outperforming the Nasdaq?

Insulet has outperformed the Nasdaq Composite over the past year and analysts remain strongly bullish about the stock’s prospects.

Barchart

Is Wall Street Bullish or Bearish on Insulet Stock?

Despite Insulet’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Barchart

Insulet Surges After Eye-Popping Earnings Growth Wallops Expectations

Insulin pump-maker Insulet walloped earnings projections and delivered strong sales, leading PODD stock to jump Friday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

AMD Stock, AI Play And New S&P 500 Member Lead 5 Stocks Near Buy Points

AMD and a new member of the S&P 500 lead this weekend's watch list of stocks that are riding positive trends, despite the tough economy.

Investors Business Daily

Insulet Joins S&P 500 And Gets Ready To Pump Up New Breakout With 56% Growth

After Insulet jumped on news it was joining the S&P 500, PODD stock is wound up for a breakout with earnings due.

Investors Business Daily

5 S&P 500 Stocks Near Buy Points As Recession Fears Rise

Medical stocks are holding up amid economic and market uncertainty.

Investors Business Daily

Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally

Dow giant UnitedHealth is among 5 stocks holding key support while the overall market weakens.

Investors Business Daily

IBD Stock Of The Day: Why An Analyst Says The Rich Valuation For Insulet Is Justified

Diabetes devices maker Insulet is the IBD Stock Of The Day as PODD stock hovers in a buy zone near its 21-day moving average.

Investors Business Daily

Dow Jones Futures: Market Expects This From Fed Chief Powell; 5 Stocks In Buy Zones

Several stocks flashed buy signals as the market rallied heading into Fed chief Powell's speech. Here's what to expect.

Investors Business Daily

IBD Stock Of The Day Insulet Edges Closer To A Breakout On This 'Game Changer'

Insulet is the IBD Stock Of The Day as excitement around the company's new insulin pump, Omnipod 5, drives PODD stock closer to a breakout.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg

Dexcom Inc (NYSE:DXCM) is reportedly in talks to acquire medical-device company Insulet Corporation (NASDAQ: PODD) to create a giant in diabetes devices, according to people with knowledge of the matter. According to Bloomberg, talks between the companies are ongoing, and an agreement could be reached in the coming weeks. Discussions could still be delayed or fall…

Benzinga

Insulet Q1 Earnings Beats Street View, Says Omnipod 5 Rollout Is 'Progressing Very Well'

Insulet Corporation (NASDAQ:PODD) posted Q1 profits of $27.8 million, or an EPS of $0.40, beating the consensus of $0.23. Q1 sales increased 17.1% Y/Y, or 19.3% in constant currency, to $295.4 million, exceeding the guidance range of 13% to 16% in constant currency and the consensus of $288.18 million. “We are off…

Benzinga

Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes

Insulet Corporation (NASDAQ:PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with DexCom Inc's (NASDAQ:DXCM) G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery system. Related: FDA Approves Insulet's Omnipod Automated Insulin Delivery System Patients…

Benzinga

Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20%

Insulet Corp's (NASDAQ: PODD)

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

2 Upgraded Diabetes Stocks to Add to Your Watchlist

Diabetes has become one of the leading causes of death for Americans, claiming more than 100,000 lives in 2021. But the disease’s prevalence represents promising prospects for the diabetes care devices market. Given this backdrop, analysts have recently upgraded diabetes stocks DexCom (DXCM) and Insulet (PODD). Thus, these stocks could…

Benzinga

Benzinga Pro's Top 5 Stocks To Watch For Friday, Jan. 28, 2022: PODD, KR, TEAM, GOOGL, SBUX

Today's 5 Stock Ideas: Insulet (PODD) - Shares up premarket. The company announced FDA clearance of its Omnipod 5 Automated Insulin Delivery System. Kroger (KR) - Shares down premarket. Citigroup downgraded

People

Jerome Powell

2,647 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals

173 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.